Hello Everyone!

We have hit the ground rolling this week, reviewing a massive initial edit for two story threads looking at Grant’s experiences undergoing chemotherapy in the UK.

Paul Hulligan, our assistant editor has been preparing sync pulls (our first time looking over footage to determine what we might use in the film), and he’s pulling out some pretty incredible stuff!

Whilst post production is beginning, we have also brought on Isabella Wright to manage social media and impact strategy for the film, as well as transcribing of footage. She’s previously worked with a few Australian and American documentaries in a similar role, including That Sugar Film and The Hunting Ground.

She’s based in Australia, so I’ve been up at all hours of the night on skype to get the strategy underway! Definitely interesting having meetings with someone when you’re about to go to sleep, and they’ve only just woken up!

But this is the life of independant film!

Welcome to the team, Bella!

I’ve also been really interested in a Telegraph article that came out earlier in the week, examining how generic cancer drug prices have increased by £380m a year for the past 5 years.

To quickly summarise, drugs such as Tamoxifen (used to treat breast cancer) and Busulfan (used to treat Leukaemia) are no longer patented, their prices are still 10 times more expensive than they once were.

Although these costs may not be directly passed on to the patient, it is said have an affect on what treatments are available to them, restricting choice in how to move forward with a treatment plan.

Busulfan cost 21p per tablet in 2011, and Tamoxifen cost 10p per tablet. These two drugs cost £2.61 and  £1.21 respectively in 2016 – which is 20 times more expensive than what they are being sold for in India!

The price increases delay approval of new exciting treatments due to a limit of funds, meaning they don’t reach patients who may urgently need them fast enough, “Mia Rosenblatt, from charity Breast Cancer Now, said: “If we want to close the gap on the rest of Europe in cancer outcomes, we urgently need to find ways to make effective new treatments available to NHS patients.”

As always, we want to discuss what you think – if you’d like to share any thoughts, just reply to this email.

Much love,